Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has swept the world in a pandemic. The disease (COVID-19) is characterized by acute respiratory distress, and there is an immediate need for any effective agent before the development of a vaccine. Coronavirus-19 disease (C...
Enregistré dans:
Auteurs principaux: | Carlo Perricone, Elena Bartoloni, Roberto Gerli |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Termedia Publishing House
2020
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/05c69d9bf924417f96de790ea9f6910c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Impact of colchicine on mortality in patients with COVID-19: A meta-analysis
par: Dimitrios A. Vrachatis, et autres
Publié: (2021) -
COVID-19 – rheumatic diseases and rheumatologists
par: Maria Maślińska
Publié: (2021) -
Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine
par: Dimitrios A. Vrachatis, et autres
Publié: (2021) -
Recurrence of the oxazole motif in tubulin colchicine site inhibitors with anti-tumor activity
par: Marilia Barreca, et autres
Publié: (2021) -
Update on COVID-19 vaccines and autoimmune-mediated rheumatic diseases
par: Lakshmanan Suresh
Publié: (2021)